fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Advertisment

TAVO + Keytruda demonstrated 41% overall response rate and 36% complete response in a late-stage metastatic melanoma study featured in ‘Clinical Cancer Research’.- Oncosec Medical.

Written by | 8 May 2020 | COVID-19

Oncosec Medical announced published data in Clinical Cancer Research that demonstrated its lead product candidate, TAVO (interleukin-12 or “IL-12” plasmid), in combination with the anti-PD-1 checkpoint inhibitor Keytruda (pembrolizumab), produced a 41% overall response rate (ORR), with 36% complete response in a Phase II, single arm study evaluating patients with metastatic melanoma selected to be anti-PD-1 checkpoint resistant.

In the trial, responses were observed in nine of 22 evaluable patients, for an objective response rate of 41 percent. Thirty-six percent of patients experienced a complete response. Median progression-free survival was 5.6 months, with median overall survival not yet reached after a median follow-up of 19.6 months. Grade 3 or higher adverse events were limited and included pain, chills, sweat and cellulitis, as well as certain toxicities usually observed with immune checkpoint inhibitors such as pembrolizumab. The results published in Clinical Cancer Research were also highlighted in a recent press release issued by the American Association for Cancer Research.

“This study provided evidence of how TAVO may convert immunologically ‘cold’ melanomas to ‘hot’ and enable checkpoint monotherapies, like Keytruda, to be more effective with minimal side effects,” said Daniel J. O’Connor, President and CEO of OncoSec. “These findings provided the clinical rational for our ongoing pivotal KEYNOTE-695 study of Tavo and Keytruda combination therapy in patients with anti-PD-1 checkpoint resistant metastatic melanoma. Because KEYNOTE-695 is treating patients with late-stage metastatic melanoma who have no FDA approved treatment options, nearly all study sites remain open and are actively recruiting patients during the current COVID-19 pandemic”.

Following completion of the KEYNOTE-695 study OncoSec intends to file for accelerated U.S. approval.

See- “Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma”-Alain P. Algazi et al.Clinical Cancer Research published 6 May 2020 DOI: 10.1158/1078-0432.CCR-19-2217

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.